Faculty profile

Valérie Martel-Laferrière

ResearcherMicrobiologie-infectiologie et d'immunologieUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses and email address may be missing. Find their university profile.

Valérie Martel-Laferrière

Researcher

Microbiologie-infectiologie et d'immunologie

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
4 publications in the last five years, latest in 2026.
Principal investigator on 7 research grants (7 CIHR), most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

People Who Inject Drugs Cohort Harm Reduction Healthcare Services Qualitative Methods Quantitative Methods Stbbi Prevention Women Who Use Drugs

Latest papers

The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study
Canadian Journal of Public Health · 2026
Evaluation of the virtual care experience for persons in prospective cohorts with HIV during the COVID pandemic
PLOS Digital Health · 2025
Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study.
Open forum infectious diseases · 2024

All 11 publications

Latest funding

From Knowledge to Action: Mobilizing the Women-Centred HIV Care Clinic Implementation Package (W-CIP) in Ontario and Quebec using RE-AIM
CIHR · 2026 · Co-investigator
$975,376
Feasibility and acceptability of sexually transmitted and blood-borne infections screening of partners of pregnant persons
CIHR · 2025 · Nominated PI
$439,874
Building Capacity in Innovative Adaptive Trial Designs for HIV and STBBI Research: The CTN-Québec Training Platform
CIHR · 2025 · Co-investigator
$800,000

All 22 grants and awards

11 publications.

The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study

Young J, Wang S, Knight M, Cardinal CL, Cooper CL, Cox J, Hull M, Martel-Laferriere V, Sutherland DJ, Walmsley S

Canadian Journal of Public Health2026

DOI: 10.17269/s41997-026-01193-y

Evaluation of the virtual care experience for persons in prospective cohorts with HIV during the COVID pandemic

Walmsley SL, Nabipoor M, Martel-Laferriere V, Loutfy M, Cooper C, Vachon M-L, Boyachuk B, Aldebes P, Klein MB, Group C-CS-S

PLOS Digital Health20252 citations

DOI: 10.1371/journal.pdig.0000857

Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study.

Saeed S, Thomas T, Dinh DA, Moodie E, Cox J, Cooper C, Gill J, Martel-Laferriere V, Panagiotoglou D, Walmsley S, Wong A, Klein MB

Open forum infectious diseases2024

DOI: 10.1093/ofid/ofae239 PMID: 38798898

Opt-out universal HCV and HIV screening in a Canadian emergency room: a cross-sectional study.

Martel-Laferriere V, Baril JG, Alarie I, Leblanc J, Côté J, Jourdenais E, Horth D, Lambert G, Tremblay C

BMJ open2022First author

DOI: 10.1136/bmjopen-2021-048748 PMID: 35042704

Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Kronfli N, Young J, Wang S, Cox J, Walmsley S, Hull M, Cooper C, Martel-Laferriere V, Wong A, Pick N, Klein MB, Canadian Coinfection Cohort Study Investigators

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

DOI: 10.1093/cid/ciaa702 PMID: 32504083

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus

Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M

Clinical Infectious Diseases202035 citations

DOI: 10.1093/cid/ciz833

Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?

Makarenko I, Artenie A, Hoj S, Minoyan N, Jacka B, Zang G, Barlett G, Jutras-Aswad D, Martel-Laferriere V, Bruneau J

The International journal on drug policy2019

DOI: 10.1016/j.drugpo.2019.04.002 PMID: 31010749

Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals

Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A

International Journal of Drug Policy201923 citations

DOI: 10.1016/j.drugpo.2018.08.012

Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals

Saeed S, Moodie EEM, Strumpf E, Gill J, Wong A, Cooper C, Walmsley S, Hull M, Martel‐Laferriere V, Klein MB

Journal of Viral Hepatitis201830 citations

DOI: 10.1111/jvh.12985

Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.

Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB, Canadian Co-Infection Cohort Study

Journal of the International AIDS Society2017

DOI: 10.1002/jia2.25013 PMID: 29116684

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2025

Subject: Prospective PhD student: People Who Inject Drugs Dear Professor Martel-Laferrière, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Feasibility and acceptability of sexually transmitted and blood-borne infections screening of partners of pregnant persons" (2025), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Valérie Martel-Laferrière

Research

Latest papers

Latest funding

The risk of HIV and HCV transmission in Canadians living with coinfection before, during, and after the COVID pandemic: A prospective cohort study

Evaluation of the virtual care experience for persons in prospective cohorts with HIV during the COVID pandemic

Frequent Disengagement and Subsequent Mortality Among People With HIV and Hepatitis C in Canada: A Prospective Cohort Study.

Opt-out universal HCV and HIV screening in a Canadian emergency room: a cross-sectional study.

Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus

Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?

Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals

Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals

Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.

Frequent collaborators

Curtis Cooper

Sharon Walmsley

Mark Hull

Sharon Walmsley

Shariq Haider

Sahar Saeed

John Gill

Curtis Cooper

Curtis Cooper

Erin Strumpf

Sharon Walmsley

Sahar Saeed

Curtis Cooper

Mark Tyndall

Julie Bruneau

Mark Tyndall

Nadine Kronfli

Dimitra Panagiotoglou

Mona Loutfy

Neora Pick

Didier Jutras-Aswad

Erica Moodie

John Gill